In the long battle against cancer, human beings have moved from chemotherapy and radiation to targeted drugs, and now to cell-based therapies.Among these innovations, CAR-T cell ...
ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...